Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Irene Kolm"'
Autor:
Birgit Bossenmaier, Gerhard Niederfellner, Karl-Peter Hopfner, Irene Kolm, Gabriele Hoelzlwimmer, Valeria Lifke, Ulrike Reiff, Christian A. Gerdes, Thomas Friess, Nikolaos Dimoudis, Michael Schräml, Christian B. Schiller, Christian Mirschberger
PDF file - 470K, Calculation of tumor growth inhibition. Tumor growth inhibition was calculated compared with respective controls using a standard formula. Surface plasmon resonance. Calculation of kinetic parameters ka (1/Ms), kd (1/s) and KD (M) of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3feaa2dd38c3bfb8639bb45849ca3ac9
https://doi.org/10.1158/0008-5472.22400820.v1
https://doi.org/10.1158/0008-5472.22400820.v1
Autor:
Ulrike Reiff, Irene Kolm, Gerhard Niederfellner, Thomas Friess, Nikolaos Dimoudis, Birgit Bossenmaier, Valeria Lifke, Thomas von Hirschheydt, Ekkehard Moessner, Christian Gerdes, Gabriele Hoelzlwimmer, Helmut Burtscher
Publikováno v:
Cancer Research. 72:2508-2508
HER3 is a member of the Human Epidermal Growth Factor Receptor (HER) family. HER3 is a kinase dead receptor, but by forming heterodimers with other HER family receptors, HER3 works as amplifier for PI3 kinase driven tumorigenesis. It has been reporte
Autor:
Gabriele Hölzlwimmer, Marlene Thomas, Birgit Bossenmaier, Irene Kolm, Thomas Friess, Georgina Meneses-Lorente, Christophe Meille, Sabine Bader
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose RG7116 is a novel anti-HER3 therapeutic antibody that inhibits HER3 signalling and induces antibody-dependent cellular cytotoxicity of tumor cells due to a glycoengineered antibody Fc moiety. We investigated the efficacy and pharmacokinetic/p